EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Effect of the Combination of Temozolomide and Flubendazole on Glioblastoma Cells

Katerina Kapickova iD, Barbora Vitovcova, Veronika Skarkova, Radim Havelek iD, Adam Skarka, Hana Vosmikova iD, Jiri Soukup, Eliska Kohoutova, Petra Matouskova iD, Emil Rudolf iD

Cells · 09.07.2026 · 15 (14) · 1239

DOI: 10.3390/cells15141239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 09.07.2026. Verfasst von Katerina Kapickova und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology and Genetics, Faculty of Medicine in Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Repu…. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, Mebendazole, Brain Neoplasms. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charles University, Cooperatio Program provided by Charles University, Faculty of Medicine in Hradec Kralove, Charles University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma multiforme (GBM) is a highly aggressive brain tumor characterized by rapid development of chemoresistance and poor patient survival. Due to the limited efficacy of current therapeutic protocols, alternative approaches are needed. One potential strategy is combined treatment with DNA-damaging and microtubule-targeting agents. This study investigated the biological effects of temozolomide (TMZ) and flubendazole (FLU) co-treatment in cultured GBM cells. Three GBM cell lines (A172, T98G, and U118MG) with different molecular profiles were treated with TMZ, FLU, or their combination. Treatment effects were evaluated using WST-1 assay, microscopy, flow cytometry, RT-PCR, and Western blotting. Drug accumulation in tumor and brain tissues was additionally analyzed in a nu-nu mouse model using LC/MS. Combined TMZ and FLU treatment reduced cell proliferation compared with untreated control and TMZ monotherapy in the tested GBM cell lines. FLU-containing treatments were associated with morphological alterations, caspase activation, altered microtubule organization, and G2/M cell cycle accumulation. In addition, co-administration of TMZ and FLU affected drug accumulation in vitro and in brain and tumor tissues in vivo. These findings suggest that the microtubule targeting may modulate the response of GBM cells to TMZ. However, the pharmacological interaction and potential relevance of TMZ + FLU co-treatment require further preclinical validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideGlioblastomaMebendazoleBrain NeoplasmsHumansAnimalsCell Line, TumorCell ProliferationMiceMice, NudeApoptosisMicrotubulesXenograft Model Antitumor Assays

Stichwörter der Autor:innen

cell cyclecombination therapyflubendazoleglioblastomamicrotubulestemozolomide

Substanzen

TemozolomideflubendazoleMebendazole

Autor:innen und Institutionen

  • Department of Medical Biology and Genetics, Faculty of Medicine in Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Republic.
  • Department of Biology, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655/76, 323 00 Pilsen, Czech Republic.
  • Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Republic.
  • Department of Chemistry, Faculty of Sciences, University of Hradec Kralove, Hradecka 1285, 500 03 Hradec Kralove, Czech Republic.
  • The Fingerland Department of Pathology, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic.
  • Department of Pathology, Military University Hospital Prague, U Vojenske Nemocnice 1200, 169 02 Prague, Czech Republic.

ORCID-Profile: Katerina Kapickova, Radim Havelek, Hana Vosmikova, Petra Matouskova, Emil Rudolf

Förderung

  • Charles University
  • Cooperatio Program provided by Charles University
  • Faculty of Medicine in Hradec Kralove, Charles University

Zitieren

APA

Kapickova, K., Vitovcova, B., Skarkova, V., Havelek, R., Skarka, A., Vosmikova, H., Soukup, J., Kohoutova, E., Matouskova, P., & Rudolf, E. (2026). The Effect of the Combination of Temozolomide and Flubendazole on Glioblastoma Cells. Cells, 15(14), 1239. https://doi.org/10.3390/cells15141239

Vancouver

Kapickova K, Vitovcova B, Skarkova V, Havelek R, Skarka A, Vosmikova H, et al. The Effect of the Combination of Temozolomide and Flubendazole on Glioblastoma Cells. Cells. 2026;15(14):1239. doi:10.3390/cells15141239

BibTeX
@article{Kapickova2026,
  author = {Kapickova, Katerina and Vitovcova, Barbora and Skarkova, Veronika and Havelek, Radim and Skarka, Adam and Vosmikova, Hana and Soukup, Jiri and Kohoutova, Eliska and Matouskova, Petra and Rudolf, Emil},
  title = {The Effect of the Combination of Temozolomide and Flubendazole on Glioblastoma Cells},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {14},
  pages = {1239},
  doi = {10.3390/cells15141239}
}
Kostenlos starten →